image credit- shutterstock
Avance Clinical, a leading full-service global Contract Research Organization (CRO) specialising in high-quality, agile clinical biotech research services, has announced the signing of four Memorandums of Understanding (MOUs) with key clinical trial sites in Taiwan- Taichung Veterans General Hospital (TCVGH); Taipei Medical University (TMU); China Medical University Hospital (CMUH); and Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH).
These new partnerships mark a strategic expansion into Taiwan, reinforcing Avance Clinical’s commitment to providing US biotechs with access to high-quality clinical research solutions across the Asia-Pacific region.
TCVGH is a leader in advanced CAR-T cell immunotherapy, ranking the second in Taiwan for the number of treated cases and achieving a 100% of cure rate. “This partnership will accelerate the development of cancer treatments and other groundbreaking therapies, bringing life-changing benefits to patients worldwide”, said Professor Yun-Ching Fu, the Dean of TCVGH.
"This partnership enhances our medical centres’ ability to make a significant impact, strengthens our presence in global trials, and ultimately improves healthcare through innovation,” said Professor Chun-Che Shih, Executive Vice President of Taipei Medical University.
Professor Der-Yang Cho, Dean of CMUH, emphasised the significance of the partnership, “This agreement not only enhances our ability to support global biotech companies but also accelerates the delivery of innovative treatments to patients.”
“Our partnership with Avance Clinical is incredibly valuable to KMUH as it allows us to connect with innovative biotech companies from around the world and bring cutting-edge clinical trials to Taiwan,” said Jaw-Yuan Wang, Superintendent of Kaohsiung Medical University Chung-Ho Memorial Hospital. “By combining our clinical research expertise and diverse patient population with Avance Clinical’s global trial management capabilities, we can accelerate the development of new therapies and provide our patients with earlier access to groundbreaking treatments.”
These agreements reinforce Avance Clinical’s GlobalReady model, offering biotech companies a seamless pathway to leverage the region’s clinical trial capabilities, regulatory efficiencies, and patient access.
